Results 261 to 270 of about 46,788 (276)

In Silico Analysis for Determination and Validation of Human CD20 Antigen 3D Structure

International Journal of Peptide Research and Therapeutics, 2017
CD20 has been known as an attractive therapeutic target for refractory diseases such as B-cell chronic lymphocytic leukemia, rheumatoid arthritis and multiple sclerosis. Determining the 3D structure of the CD20 antigen could help to achieve a better deduction of its functions and its interactions with ligands.
Zahra Payandeh, Azam Rahimpour, Masoumeh Rajabibazl, Yousef Mortazavi   +3 more
openaire   +2 more sources

GM-CSF does not increase CD20 antigen expression on chronic lymphocytic leukemia lymphocytes

Leukemia Research, 2005
CD20 antigen expression in B-chronic lymphocytic leukemia (B-CLL) is at significantly lower levels than in non-Hodgkins lymphoma, which may affect the degree of anti-CD20 antibody binding. Low density of CD20 expression on malignant cells may explain the lower response rates to anti-CD20 monoclonal antibody, observed in B-CLL.
Yagci, M, Akar, I, Sucak, GT, Haznedar, R   +3 more
openaire   +4 more sources

Improved antigen binding by a CD20-specific single-chain antibody fragment with a mutation in CDRH1

Molecular Immunology, 2006
We have prepared single-chain immunoglobulin Fv fragments from the CD20-specific hybridoma HB13d. One scFv clone demonstrated strong binding to a CD20-derived peptide by ELISA and to CD20-positive cells by flow cytometry, a second had reduced binding, and a third clone did not bind the target antigen.
Glenn R Pilkington, Peter J. Macardle, Peter J. Macardle, Ian C. Nicholson, Ian C. Nicholson, Thomas F. Tedder, Terrence D. Mulhern, Penny Adamson, Heddy Zola, Heddy Zola, Heddy Zola, Chris Mavrangelos, Arthur W. Hohmann, Debbrah Millard   +13 more
openaire   +4 more sources

Effect of interferon-α on CD20 antigen expression of B–cell chronic lymphocytic leukemia

Cytokines, Cellular & Molecular Therapy, 2000
Chimeric CD20 monoclonal antibody as alternative therapy in relapsed low-grade non-Hodgkin's lymphoma (NHL) has produced responses in nearly 50% of patients. Augmenting CD20 expression on tumor cells and/or inducing its expression may increase the cell kill and effectiveness of antibody therapy. Peripheral blood lymphocytes from 19 patients with B-cell
Teresa O'Brien, A. Jajeh, Xiao-Ke Huang, Stephanie A. Gregory, Harvey D. Preisler, S. Sivaraman, Charuhas Deshpande, Parameswaran Venugopal, R. Ranganathan   +8 more
openaire   +2 more sources

Cd20 (pan‐B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes

Cytometry, 1993
AbstractDespite the previous description of the leukocyte differentiation antigen CD20 as B cell restricted, the findings reported here indicate that a small subset of human T cells expresses low levels of CD20 or a cross‐reacting antigen. Three different CD20 monoclonal antibodies (mAb), Leu16, B1, and 1F5, reacted with the T cell subset. B cells that
Janis V. Giorgi, Lance E. Hultin, Mary Ann Hausner, Patricia M. Hultin   +3 more
openaire   +3 more sources

Construction and Characterizationc of a Camelized, Human, VH-based Peptide Vaccine Against CD20 Antigen

Immunotherapy, 2013
The purpose of this study was to construct and characterize a camelized, human, heavy-chain variable (VH) fragment-based peptide vaccine against CD20 antigen.Camelized, human VH with improved solubility and stability was used as a vaccine scaffold. A CD20 B-cell epitope was introduced into the complementarity determining region 3 of the engineered VH ...
Ranxing Zhang, Jianbin Liu, Yanguo Tan
openaire   +3 more sources

CD20 antigen imaging with ¹²⁴I-rituximab PET/CT in patients with rheumatoid arthritis.

Human antibodies, 2011
Visualization of the CD20-antigen expression could provide a tool to localize sites of inflammation and could be of additive value in the diagnosis, and subsequently, in the treatment follow-up of patients with rheumatoid arthritis. In this study, an anti-CD20 monoclonal antibody, rituximab (Mabthera®), was radiolabeled with ¹²⁴Iodine.
W V Vogel, Jos H. Beijnen, Jos H. Beijnen, L Tran, H.J. Dinant, M H van Rijswijk, Joke W. Baars, A. D. R. Huitema   +7 more
openaire   +3 more sources

Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1).

The Journal of Immunology, 1989
Abstract The CD20 (B1) molecule is a differentiation Ag found only on the surface of B lymphocytes. This structurally unique phosphoprotein plays a role in the regulation of human B cell proliferation and differentiation. In this report genomic DNA clones containing the human CD20 gene were isolated and the structure of the CD20 gene ...
T F, Tedder, G, Klejman, S F, Schlossman, H, Saito   +3 more
openaire   +2 more sources

Effect of Rituximab On the Activity of T Cells Expressing CD20-Specific Chimeric Antigen Receptors

Blood, 2012
Abstract Abstract 4222 BACKGROUND: Adoptive cellular therapy using autologous T cells that have been genetically modified to express a chimeric antigen receptor (CAR) has emerged as a promising therapy for lymphoma.
Gregory A. Rufener, Michael C. Jensen, David G. Maloney, Lihua E. Budde, Oliver W. Press, Shaunda A. Brouns, Brian G. Till   +6 more
openaire   +2 more sources

Target cell killing effects of CD20 targeting chimeric antigen receptor T cells derived from the type II anti-CD20 antibody.

Journal of Clinical Oncology, 2017
e14548 Background: Chimeric Antigen Receptor T cells (CAR-Ts) targeting CD19 have shown very promising clinical outcomes in treatment of B-cell linage hematological malignancies. However, many patients with relapsed diseases were found to have down-regulated/loss of CD19 surface expression after CD19 CAR-T therapy.
Li Yanfeng, Li Zhiyuan, Chengxiang Dai, Wei Zhu, Wei Yutian, Xin Yao, Wang Qingxia, Ma Anyun, Zhu Shigui, Li Zhang, Bizuo Liu, Yihong Yao, Jiaqi Huang, Zhu Lin   +13 more
openaire   +2 more sources